WESTCHESTER COUNTY LIFE SCIENCES UPDATE

Sapience Therapeutics Receives Clearance from FDA to Proceed with Phase 1-2 Study in Patients with Solid Tumors

Harrison’s Sapience Therapeutics, Inc., announced the U.S. Food and Drug Administration (FDA) cleared the Company to proceed with its Phase 1-2 clinical trial of ST316 for the treatment of solid tumors. Sapience expects to begin patient dosing in the Phase 1 dose escalation portion of the study in the first half of 2023 to evaluate the safety, clinical activity, pharmacokinetics and pharmacodynamics of ST316.

The Phase 1 dose-escalation portion of the study is designed as a basket study to enroll patients with tumors likely to harbor abnormalities of the Wnt/β-catenin signaling pathway. The Phase 2 dose-expansion portion of the study will enroll patients in four specific tumor types known to harbor abnormalities of the Wnt/β-catenin signaling pathway, including cholangiocarcinoma, colorectal, triple negative breast and ovarian cancers.

Sapience Therapeutics Announces Late-Breaking Research Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023

Sapience Therapeutics, Inc., a clinical biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced it will present two late-breaking research posters during the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, in Orlando, Florida.

Poster Presentation Details:

Title: "ST101, a peptide antagonist of novel I/O target C/EBPβ, reprograms MDSCs and promotes an immunoactive tumor microenvironment"

Cognition to Commence Phase II Trial of

Dry AMD Drug Candidate

Purchase-headquartered Cognition Therapeutics announced plans to commence the Phase II MAGNIFY clinical trial of its oral drug candidate, CT1812, for dry age-related macular degeneration (dry AMD) this year.

The company’s decision comes after its investigational new drug (IND) application to study CT1812 for geographic atrophy (GA) secondary to dry AMD received clearance from the US Food and Drug Administration (FDA).

The randomized, placebo-controlled Phase II MAGNIFY trial (COG2201) is expected to enroll nearly 246 people diagnosed with dry AMD with measurable GA.

Students Win More Than $1.8 Million at

2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease

Tarrytown’s Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Neel Moudgal, 17, of Saline, Mich., won the top $250,000 award in the 2023 Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.

Eighth place went to Samantha Milewicz, 17, of Armonk, N.Y., who received a $60,000 award for examining the immune reaction to a traumatic brain injury and found that it can trigger the body to overproduce an enzyme that degrades the protein that holds the cells of the blood-brain barrier together, causing it to leak.

The competition, now in its 82nd year, celebrates and rewards young scientists focused on a wide range of scientific topics. This year, those topics include everything from cancer research to climate change to the space race and more. Forty finalists, including Neel, were honored during a livestreamed award ceremony emceed by American Broadcaster Soledad O'Brien. More than $1.8 million was awarded to the finalists, who were evaluated based on their projects' scientific rigor, their exceptional problem-solving abilities and their potential to become leaders in STEM.

Have good news to share with

Westchester’s life sciences ecosystem?

Please let us know.

Email lifesciences@westchestergov.com.